Legal & General Group Plc Takes Position in DaVita Inc. $DVA

Legal & General Group Plc acquired a new position in DaVita Inc. (NYSE:DVA) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 90,009 shares of the company’s stock, valued at approximately $20,025,000. Legal & General Group Plc owned about 0.14% of DaVita as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the stock. The Manufacturers Life Insurance Company acquired a new position in DaVita during the 2nd quarter worth about $6,539,000. Algert Global LLC increased its stake in shares of DaVita by 28.4% in the second quarter. Algert Global LLC now owns 7,820 shares of the company’s stock valued at $1,740,000 after buying an additional 1,730 shares during the period. Cibc World Market Inc. bought a new position in shares of DaVita during the second quarter worth about $3,060,000. Sanctuary Advisors LLC acquired a new position in shares of DaVita in the second quarter worth approximately $1,956,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in DaVita in the second quarter valued at approximately $9,208,000. 90.12% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

DVA has been the subject of several analyst reports. Zacks Research lowered shares of DaVita from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Oppenheimer set a $220.00 price objective on shares of DaVita in a research note on Friday, August 7th. Raymond James Financial set a $220.00 price objective on shares of DaVita in a research report on Friday, August 7th. Truist Financial dropped their target price on shares of DaVita from $250.00 to $215.00 and set a “hold” rating on the stock in a report on Friday, August 7th. Finally, Barclays upped their price target on shares of DaVita from $218.00 to $224.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 5th. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $221.75.

DaVita Stock Up 1.0%

Shares of DVA stock opened at $180.72 on Friday. The firm has a 50 day moving average of $211.96 and a 200-day moving average of $183.05. The company has a market cap of $11.53 billion, a price-to-earnings ratio of 14.79, a price-to-earnings-growth ratio of 0.47 and a beta of 0.88. DaVita Inc. has a 52 week low of $101.00 and a 52 week high of $247.49.

DaVita (NYSE:DVA) last released its earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.88 by $0.14. The company had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.50 billion. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. DaVita’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.95 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Analysts anticipate that DaVita Inc. will post 14.57 earnings per share for the current year.

Insider Buying and Selling at DaVita

In other news, insider Kathleen Alyce Waters sold 15,405 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the transaction, the insider owned 109,194 shares of the company’s stock, valued at $22,756,029.60. This represents a 12.36% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.90% of the company’s stock.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.